AdamJanOlszewskiMD

PubMed

• Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
  Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
  Journal of Clinical Oncology. 2024-12-07
• High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.
  Narendranath Epperla, Adam S Zayac, Daniel J Landsburg, Allison M Bock, Grzegorz S Nowakowski
  Blood Advances. 2024-10-22
• 1 citations
  Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.
  Natalie S Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali
  Blood Cancer Journal. 2024-10-18

Abstracts/Posters

• BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Billed Palliative Care Services and End-of-Life Care in Patients with Hematologic Malignancies
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Geographic Variation in the Incidence of Marginal Zone Lymphoma Subtypes and Infectious Risk Factors in the United States
  Adam J Olszewski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence
  Adam Olszewski, MD, Current Treatment Options in Oncology, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Loss of Abelson Interactor-1 Is Linked to Inflammatory Hematopoiesis and Accelerated Aging of Hematopoietic System 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hospice use among Medicare fee-for-service (FFS) or managed-care organization (MCO) enrollees with leukemia and myeloma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all